Eating Against Yourself Part 2: The Loop

Edited and approved by Stephen C. Rose, PhD, MS

The switch is mTORC1 on one side, AMPK on the other, and a molecular logic that was built for a world of alternating feast and famine. In that world, the switch flipped regularly. Neither side stayed dominant for long. The modern environment broke that rhythm — and when the switch got stuck, something else happened that is more consequential than a switch simply being in the wrong position. A feedback loop formed. The stuck switch began generating the conditions that kept it stuck. And once that loop is running, the familiar tools — eating less, trying harder, starting over — can make it worse rather than better.

This is the biology that underlies what medicine calls metabolic syndrome. Not as five separate problems that happened to cluster in the same unlucky person, but as five readings of a single broken signal — one stuck switch expressing itself simultaneously across the cardiovascular system, the liver, the pancreas, and adipose tissue. Understanding the loop changes how you read your own lab results, your own body's resistance, and your own history with dieting.

How the Switch Gets Stuck: The Insulin Resistance Loop

The loop begins with a molecule called S6K1 — ribosomal protein S6 kinase 1 — which is one of mTORC1's primary downstream targets. When mTORC1 activates, one of its first actions is to phosphorylate and activate S6K1, which then drives protein synthesis and cell growth. So far, this is normal and healthy. The problem is that S6K1 has a second function that becomes destructive under chronic activation: it phosphorylates insulin receptor substrate 1, known as IRS-1, at specific inhibitory sites. [1][2]

IRS-1 is the critical docking protein that carries the insulin signal from the cell surface into the interior. When IRS-1 is phosphorylated at those inhibitory sites by S6K1, it uncouples from the insulin receptor and is tagged for degradation. The cell that was supposed to hear the insulin signal — open your glucose channels, take up nutrients, respond to the fed state — goes partially deaf to it. This is insulin resistance: not a failure of insulin production, but a failure of insulin signaling at the cellular level. [1][3]

The pancreas interprets silence as insufficiency. It responds by secreting more insulin. More insulin drives more mTORC1. More mTORC1 drives more S6K1. More S6K1 destroys more IRS-1. The loop tightens.

What makes this a positive feedback loop rather than a self-limiting response is that the compensatory mechanism — more insulin — is the same signal that activated mTORC1 in the first place. The pancreas cannot distinguish between genuine insulin insufficiency and insulin resistance caused by mTORC1 overactivation. It sees glucose not being cleared efficiently and does the only thing it can: produce more insulin. More insulin binds to cell surface receptors, activates PI3K and AKT, and drives mTORC1 harder. The loop has no internal brake. Left uninterrupted, it tightens with each cycle. [2][3][4]

What Makes It Worse Over Time

The loop does not run at a steady state. Three aging-specific processes amplify it progressively, which is why metabolic dysfunction tends to accelerate rather than plateau as people get older. [5][6]

The first amplifier is visceral adipose inflammation. As mTORC1 drives fat storage — through SREBP-1c and the lipogenic program described earlier in this series — visceral fat accumulates around the abdominal organs. Visceral adipose tissue is not metabolically inert. As it expands, it recruits immune cells called macrophages that begin secreting inflammatory cytokines, primarily TNF-alpha and IL-1 beta. Both cytokines directly phosphorylate IRS-1 at the same inhibitory serine residues that S6K1 targets — through separate pathways involving JNK and IKK beta respectively. The result is that visceral fat accumulation, itself a consequence of mTORC1 overactivation, adds an entirely independent source of IRS-1 impairment that amplifies insulin resistance without any further input from nutrient signaling. [5][6]

The second amplifier is ectopic lipid deposition. Fat that cannot be stored efficiently in adipose tissue begins accumulating in skeletal muscle and liver — tissues that are not designed for lipid storage. In muscle, intracellular lipid accumulation generates ceramides and diacylglycerol, both of which activate protein kinase C theta, which — again — phosphorylates IRS-1 at inhibitory sites. Muscle insulin resistance then reduces the primary tissue for postprandial glucose disposal, worsening the hyperglycemia that drives more insulin secretion. In liver, ectopic fat accumulation drives non-alcoholic fatty liver disease and hepatic insulin resistance, which impairs the liver's ability to suppress glucose production overnight, raising fasting glucose levels independently of dietary intake. [7][8]

The third amplifier is beta cell exhaustion. The pancreatic beta cells that have been overproducing insulin for years begin to fail. Chronic hyperinsulinemia induces endoplasmic reticulum stress in beta cells, generates oxidative damage, and eventually drives beta cell senescence and death. As insulin secretory capacity declines, the compensatory mechanism that was sustaining the loop becomes unreliable. Postprandial glucose spikes become larger and more prolonged. The person moves along a continuum that conventional medicine divides into discrete diagnoses — pre-diabetes, then type 2 diabetes — but which is, mechanistically, the same loop that has been running for years finally overwhelming its own compensatory capacity. [4][9]

Metabolic Syndrome: Five Gauges, One Engine

Metabolic syndrome is diagnosed when three or more of five clinical criteria are present: abdominal obesity, elevated fasting triglycerides, low HDL cholesterol, elevated fasting glucose, and hypertension. The standard framing treats these as a cluster — related risk factors that tend to co-occur. The framing that emerges from the loop biology is more precise: they are five organ-system expressions of the same upstream dysfunction. [7][10]

Abdominal obesity is mTORC1-driven lipogenesis accumulating in visceral depots. Elevated triglycerides are the hepatic output of SREBP-1c activation, combined with reduced clearance from impaired lipoprotein lipase activity downstream of insulin resistance. Low HDL follows mechanistically from hypertriglyceridemia through cholesterol ester transfer protein activity — triglyceride-rich VLDL particles exchange their cargo into HDL, making HDL particles lipid-laden and unstable, accelerating their clearance. Elevated fasting glucose is the direct readout of peripheral and hepatic insulin resistance. Hypertension is driven partly by hyperinsulinemia itself, which stimulates renal sodium retention and sympathetic nervous system activation, and partly by the endothelial dysfunction that accompanies chronic low-grade inflammation.

Metabolic syndrome is not five problems. It is one problem — a stuck switch and the feedback loop it generates — measured at five different organ systems simultaneously.

This reframing has a practical implication that the conventional five-factor model misses: treating any single criterion in isolation, without addressing the underlying loop, is treating a gauge rather than the engine. Lowering triglycerides with a fibrate, or raising HDL with niacin, or managing blood pressure with an antihypertensive, leaves the loop running. The clinical history of metabolic syndrome treatment is substantially a history of this exact pattern — interventions that moved individual numbers without altering the underlying biology, producing modest improvements in markers while the engine continued driving the same downstream damage. Understanding this is not an argument against medication when it is needed. It is an argument for understanding what the medication is and is not doing. [7][10]

Follow the loop forward in time and it moves into the cell, into the mitochondria, and into the accumulation of senescent cells that converts a metabolic problem into an aging problem. The loop does not just make you sick. Run long enough, it measurably accelerates biological age in ways that are now quantifiable from a blood sample — and potentially reversible, if you understand what you are reversing.